The latest evidence shows that peripheral blood interlekin‐6 (IL‐6) levels, a critical mediator of respiratory failure, shock, and multiorgan dysfunction, were significantly increased in COVID‐19 patients who had used a RAAS inhibitor.8, 9. This evidence concerns the gene IL6 and COVID-19.